David A. Wenger, PhD

David A. Wenger, PhD

Contact Dr. Wenger

1020 Locust Street
Room 394
Philadelphia, PA 19107

(215) 955-1666
(215) 955-9554 fax

Most Recent Peer-reviewed Publications

  1. Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study
  2. Rare Saposin A deficiency: Novel variant and psychosine analysis
  3. Biochemical and clinical response after umbilical cord blood transplant in a boy with early childhood-onset beta-mannosidosis
  4. A closer look at ARSA activity in a patient with metachromatic leukodystrophy
  5. Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months
  6. AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease)
  7. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease
  8. GM2 Gangliosidosis in Shiba Inu Dogs with an In-Frame Deletion in HEXB
  9. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State
  10. Krabbe disease: One Hundred years from the bedside to the bench to the bedside
  11. Expression of individual mutations and haplotypes in the galactocerebrosidase gene identified by the newborn screening program in New York State and in confirmed cases of Krabbe's disease
  12. A patient with atypical multiple sulfatase deficiency
  13. Newborn screening for Krabbe disease in New York State: The first eight years' experience
  14. Long-term improvements in lifespan and pathology in CNS and PNS after BMT plus one intravenous injection of AAVrh10-GALC in twitcher mice
  15. Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy
  16. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features
  17. Reprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
  18. Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases
  19. Krabbe Disease: Globoid Cell Leukodystrophy
  20. Krabbe disease: Are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations?